These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21813857)

  • 1. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.
    Watanaveeradej V; Simasathien S; Nisalak A; Endy TP; Jarman RG; Innis BL; Thomas SJ; Gibbons RV; Hengprasert S; Samakoses R; Kerdpanich A; Vaughn DW; Putnak JR; Eckels KH; Barrera Rde L; Mammen MP
    Am J Trop Med Hyg; 2011 Aug; 85(2):341-51. PubMed ID: 21813857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
    Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
    Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
    Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.
    Simasathien S; Thomas SJ; Watanaveeradej V; Nisalak A; Barberousse C; Innis BL; Sun W; Putnak JR; Eckels KH; Hutagalung Y; Gibbons RV; Zhang C; De La Barrera R; Jarman RG; Chawachalasai W; Mammen MP
    Am J Trop Med Hyg; 2008 Mar; 78(3):426-33. PubMed ID: 18337339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
    George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
    J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
    Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
    J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Gunale B; Farinola N; Yeolekar L; Shrivastava S; Girgis H; Poonawalla CS; Dhere RM; Arankalle V; Chandra Mishra A; Mehla R; Kulkarni PS
    Vaccine; 2023 Aug; 41(38):5614-5621. PubMed ID: 37532611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
    Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.
    Durbin AP; Kirkpatrick BD; Pierce KK; Elwood D; Larsson CJ; Lindow JC; Tibery C; Sabundayo BP; Shaffer D; Talaat KR; Hynes NA; Wanionek K; Carmolli MP; Luke CJ; Murphy BR; Subbarao K; Whitehead SS
    J Infect Dis; 2013 Mar; 207(6):957-65. PubMed ID: 23329850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
    Moris P; Bauer KM; Currier JR; Friberg H; Eckels KH; Esquilin IO; Gibbons RV; Innis BL; Jarman RG; Simasathien S; Sun P; Thomas SJ; Watanaveeradej V
    Hum Vaccin Immunother; 2019; 15(9):2090-2105. PubMed ID: 30829100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.
    Watanaveeradej V; Gibbons RV; Simasathien S; Nisalak A; Jarman RG; Kerdpanich A; Tournay E; De La Barrerra R; Dessy F; Toussaint JF; Eckels KH; Thomas SJ; Innis BL
    Am J Trop Med Hyg; 2014 Jul; 91(1):119-28. PubMed ID: 24865677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
    Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
    Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
    Diaz C; Lin L; Martinez LJ; Eckels KH; Campos M; Jarman RG; De La Barrera R; Lepine E; Toussaint JF; Febo I; Innis BL; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2018 May; 98(5):1435-1443. PubMed ID: 29512481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
    Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
    Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.